PHARMACOGENETIC TESTING AS AN ELEMENT OF PERSONALIZED MEDICINE IN REAL CLINICAL PRACTICE
https://doi.org/10.18705/2782-3806-2022-2-3-27-37
Abstract
Introduction. It has been proven that patients with thrombosis and with a high risk of systemic thromboembolic complications (TEС), including patients with non-valvular atrial fibrillation (AF) should receive effective and safe antithrombotic therapy [1–3]. A personalized approach to prolonged AVK therapy is associated with an improvement in hemostasiological markers of thrombinemia and clinical outcomes in patients with VTE and non-valvular AF [4–8]. Materials and methods. Prospective study was carried out on the basis of the anticoagulant clinic (AC) of the Department of hemostasis and atherothrombosis laboratory of the state budgetary health institution of the Arkhangelsk region “First city clinical hospital named after names E. E. Volosevich” (GBUZ AR FCCH). The object of the study is patients of the AVK registry who applied to the RCATT (n = 107) who underwent pharmacogenetic testing (CYP2C9, CYP4F2, VKORC1 genotype) with calculation of individual doses of warfarin and assessment of quality of life using validated questionnaires. The analysis of the effectiveness and safety of warfarin therapy was carried out. Results. It was found that complications of warfarin therapy developed regardless of the presence of the genotype (CYP2C9, CYP4F2, VKORC1) and the warfarin dosing algorithm under observation in AC. It has been shown that pharmacogenetic testing in patients with VTE and AF is an additional method under the condition of observation in AC. Conclusion. A personalized approach to prolonged VKA therapy using pharmacogenetic testing is appropriate for patients of the older age group, patients with a aggravated hemorrhagic history, frequent minor bleeding at target INR values and the presence of concomitant therapy with cytochrome P450 inhibitors.
About the Authors
A. S. Barteneva
Northern State Medical University
Russian Federation
Russian Federation
Barteneva Aleksandra S., docent of department of clinical pharmacology and pharmacotherapy
Troitskiy Ave., 51, Arkhangelsk, 163000
N. A. Vorobyeva
Northern State Medical University
Russian Federation
Russian Federation
Vorobyeva Nadezda A., doctor of medical sciences, Professor, head of the Department of clinical pharmacology and pharmacotherapy
Troitskiy Ave., 51, Arkhangelsk, 163000
References
1. Belousov YuB. Kliniko-ekonomicheskij analiz effektivnosti dabigatrana eteksilata v sravnenii s varfarinom v aspekte profilaktiki serdechno-sosudistyh oslozhnenij u pacientov s neklapannoj fibrillyaciej predserdij / Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov // Racional’naya farmakoterapiya v kardiologii. — 2012. — № 8. — S. 37–44.
2. Vorob’eva NA. Social’no-ekonomicheskoe obosnovanie sozdaniya sistemy centralizovannogo monitoringa antikoagulyantnoj terapii u pacientov v Arhangel’skoj oblasti / N. A. Vorob’eva, A. I. Vorob’eva, A. A. Shchapkov, M. Lisyanskaya, A. A. Karpunov // Sbornik tezisov 2-go Mezhdunarodnogo foruma antikoagulyantnoj terapii. — M., 2017. — S. 41–42. https://doi.org/10.17116/labs20187256-62
3. Gorbunova EV. Effektivnost’ obuchayushchej programmy u pacientov s infarktom miokarda pri analize mediko-social’nyh faktorov priverzhennosti k lecheniyu / E. V. Gorbunova, D. Yu. Sedyh, O. S. Krestova, I. A. Bryuhanova // Sibirskij medicinskij zhurnal. — 2017. — T. 32, № 3. — S. 56–59. DOI:10.29001/2073-8552-2017-32-3-56-59
4. Kropacheva ES, Borovkov NN, Vavilova TV, Vereina NK, Vorob’eva NA, Lavrinov PA, Rogozina AS. Bystrye tempy nasyshcheniya varfarinom — prediktor razvitiya chrezmernoj gipokoagulyacii. Modernizaciya algoritma podbora dozy varfarina Ateroskleroz, № 1, 2015, S. 74–86. https://doi.org/10.21518/2307-1109-2015-1-74-86
5. Mel’nik MV. Antikoagulyanty nepryamogo dejstviya v terapevticheskoj praktike lecheniya i profilaktiki venoznogo tromboza / M. V. Mel’nik, I. S. Svyatov, A. M. Shilov // Russkij medicinskij zhurnal. — 2006. — T. 14, № 10. https://doi.org/10.37489/2588-0519-2020-1-69-79
6. Novik AA. Rukovodstvo po issledovaniyu kachestva zhizni v medicine / A. A. Novik, T. I. Ionova. — M.: OLMA Media Grupp, 2007. — 320 s.
7. Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike venoznyh tromboembolicheskih oslozhnenij // Flebologiya. — 2018. — T. 12, N 3. — S. 146–240.
8. Sychev DA. Prikladnye aspekty primeneniya farmakogeneticheskogo testirovaniya dlya presonalizacii primeneniya peroral’nyh antikoagulyantov v rossijskih usloviyah / D. A. Sychev // Racional’naya farmakoterapiya v kardiologii. — 2013. — T. 9, № 5. — S. 525–535. https://doi.org/10.20996/1819-6446-2013-9-5-525-531
9. Assessing the relative potency of (S)- and (R)- warfarin with a new PK-PD model, in relation to VKORC1 genotypes / M. Ferrari, V. Pengo, M. Barolo [et al.] // European Journal Clinical Pharmacology. — 2017. — Vol. 73, Is. 6. — P. 699–707. DOI:10.1007/s00228-017-2248-9.
10. Aomori T. Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring / T. Aomori, Y. Fujita, K. Obayashi [et al.] // Journal of Clinical Pharmacy and Therapeutics. — 2014. — Vol. 39, Is. 3. — P. 319–321. DOI:10.1016/j.amjmed.2017.02.030.
11. Clarkesmith DE. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial / D. E. Clarkesmith, H. M. Pattison, G. Y. Lip, D. A. Lane // PLoS One journal. — 2013. — Vol. 8. — P. 74037. DOI:10.1371/journal.pone.0074037.
12. Heit JA. The epidemiology of venous thromboembolism in the community / J. A. Heit // Arteriosclerosis. Thrombosis and Vascule Biology. — 2008. — Vol. 28, Is.3. — P. 370–2.
13. Johnson JA. Clinical Pharmacogenetics Implementation. Consortium Guidelines for CYP2C9 and VKORC1. Genotypes and Warfarin Dosing / J. A. Johnson, L. Gong, M. Whirl-Carrillo, B. F. Gage // Journal of Clinical pharmacology and Therapeutics. — 2011. Vol. 4. — P. 625–629. DOI:10.1038/clpt.2011.185.
14. Kim TH. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonvalvular atrial fibrillation patients: A multicenter propensity-matched analysis / T. H. Kim, J. Y. Kim, H. S. Mun, H. Y. Lee [et al.] // Journal of Thrombosis and Haemostasis. — 2015. — Vol.13, Is. 2. — P.182–190. DOI:10.1111/jth.12810.
15. Takach S. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and metaanalysis / S. Takach, N. Cohen, C. Kearon // Journal of Thrombosis and Haemostasis. — 2014. — Vol.12, Is.5. — P. 595–605. DOI:10.1111/jth.12529.
16. Ware JE. SF-36 Physical and Mental Health Summary Scales: A User`s Manual / J. E. Ware, M. Kosinski, S. D. Keller // The Health Institute, New England Medical Center. — Boston, Mass, 1994. DOI:10.1097/00005650-199603000-00003.
17. You JJ. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 10th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines / J. J. You, D. E. Singer, P. A. Howard [et al.] // Chest Journal. — 2013. — P. 419–496. DOI:10.1378/chest.11-2304.
18. Zieren J. Repair of inguinal hernia in the elderly. Results of the plug and patch repair with special reference to quality of life / H. U. Zieren, F. Wenger // Chirurg. — 2000. — Vol. 71, № 5. — P. 564–567. DOI:10.1007/s001040051103.
19. Zigmond AS. The hospital anxiety and depression scale, HADS / A. S. Zigmond, R. P. Snaith // Acta Psychiatrica Scandinavica. — 1983. — Vol. 67, Is.6. — P.361–370. DOI:10.1111/j.1600-0447.1983.tb09716.x.
Review
For citations:
Barteneva A.S., Vorobyeva N.A. PHARMACOGENETIC TESTING AS AN ELEMENT OF PERSONALIZED MEDICINE IN REAL CLINICAL PRACTICE. Russian Journal for Personalized Medicine. 2022;2(3):27-37. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-3-27-37
Views:
386
Email this article 